MYD88 and colitis: In this study, we further explored the pharmacological activity and molecular mechanism of DMB in the treatment of colitis induced by TNBS, and we revealed that DMB alleviated colitis and suppressed the activation of TLR4 signaling in an MyD88-dependent and -independent manner in TNBS-induced colitis rats and LPS-induced RAW264.7 cells.